MannKind Corp Files 8-K: Material Definitive Agreement

TL;DR

MannKind signed a big deal, details TBD.

AI Summary

On August 24, 2025, MannKind Corporation entered into a material definitive agreement. The filing does not provide specific details about the agreement's nature or any associated dollar amounts. The company is incorporated in Delaware and its principal executive offices are located at 1 Casper Street, Danbury, Connecticut.

Why It Matters

This filing indicates a significant new agreement for MannKind Corporation, which could impact its business operations and future financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its potential impact.

Key Players & Entities

• MannKind Corporation (company) — Registrant
• Delaware (jurisdiction) — State of Incorporation
• 1 Casper Street, Danbury, Connecticut 06810 (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share MNKD The Nasdaq Stock Mar
• $5 million — Kind will receive an upfront payment of $5 million and is eligible to receive up to $35 mi
• $35 million — illion and is eligible to receive up to $35 million in milestone payments upon achievement

Filing Documents

• mnkd-20250824.htm (8-K) — 48KB
• mnkd-ex10_1.htm (EX-10.1) — 73KB
• 0000950170-25-111586.txt ( ) — 234KB
• mnkd-20250824.xsd (EX-101.SCH) — 24KB
• mnkd-20250824_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On August 24, 2025 MannKind Corporation ("MannKind") entered into a first amendment ("First Amendment") to the global license and collaboration agreement dated September 3, 2018 (the "License Agreement") with United Therapeutics Corporation ("United Therapeutics"). The First Amendment memorializes the exercise of United Therapeutics' option to expand the scope of the products covered by the License Agreement to include an additional development product (the "Additional Product"). Pursuant to the First Amendment, MannKind will formulate an investigational molecule using its proprietary Technosphere platform and will manufacture specified quantities of clinical trial materials for the Additional Product. United Therapeutics will conduct all other preclinical and clinical development activities. Under the terms of the First Amendment, MannKind will receive an upfront payment of $5 million and is eligible to receive up to $35 million in milestone payments upon achievement of specified development milestones related to the Additional Product, and 10% royalties on net sales of the Additional Product, if approved. The foregoing summary of the First Amendment does not purport to be complete and is qualified in its entirety by reference to the First Amendment, a copy of which is attached as Exhibit 10.1 to this report.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1*# First Amendment to License and Collaboration Agreement dated August 24, 2025 between MannKind Corporation and United Therapeutics Corporation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. # Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MannKind Corporation Date: August 27, 2025 By: /s/ David Thomson, Ph.D., J.D. David Thomson, Ph.D., J.D. Executive Vice President, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR